Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE is a synthetic small molecule with the molecular formula C20H14Cl2N4O3S. It belongs to the imidazo[1,2-a]pyridine class of compounds, which are recognized as a privileged scaffold in medicinal chemistry due to their diverse biological activities. While specific detailed mechanisms of action for this exact compound are not readily available, the broader class of imidazo[1,2-a]pyridine derivatives has been investigated for various pharmacological effects, including anticancer, antituberculosis, antibacterial, antiviral, anti-inflammatory, antidiabetic, and antiplasmodial properties. Some derivatives have been shown to inhibit targets such as CDK, VEGFR, PI3K, EGFR, RGGT, and act as CXCR4 receptor antagonists, or ligands for the 18-kDa translocator protein (TSPO). This compound is classified as a pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE.